Polypharmacy is common in older adults with cancer and deprescribing potentially inappropriate medications becomes very relevant when life expectancy decreases due to metastatic disease. Especially preventive medications may no longer be beneficial, because they may decrease quality of life and reduction in morbidity and mortality may be futile. Although deprescribing of preventive medication is common in the last period of life, it is still unusual during active cancer treatment for advanced disease, although life expectancy is often limited to less than 1 to 2 years in that stage. We performed a systematic search of the literature in Pubmed and Embase on the discontinuation of commonly utilized groups of preventive medication and evaluated the evidence of potential benefits and harms in patients aged 65 years or older with cancer and a limited life expectancy (LLE). From 21 included studies, it can be concluded that deprescribing lipid lowering drugs, antihypertensive drugs, osteoporosis drugs and antihyperglycemic drugs is feasible in a considerable part of patients with a LLE. Discontinuation may be performed safely, without the occurrence of serious adverse events or decrease of survival. The only study that addressed quality of life after deprescribing showed that discontinuation of statins improves quality of life in patients with a LLE. Recurrence of symptoms requiring reintroduction occurred in 0-13% of patients on antihyperglycemic treatment and 8-60% of patients using antihypertensive drugs. In order to reduce pill burden and futile treatment clinicians should discuss deprescribing of preventive medication with older patients with advanced cancer and a LLE.
FrazierSC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs. 2005;31(9):4–11.
2.
GarfinkelDManginD. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170(18):1648–1654.
3.
LavanAHGallagherPParsonsCO’MahonyD. STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): consensus validation. Age Ageing. 2017;46(4):600–607.
4.
ScottIAAndersonKFreemanCRStowasserDA. First do no harm: a real need to deprescribe in older patients. Med J Aust. 2014;201(7):390–392.
5.
ScottIAHilmerSNLe CouteurDG. Going beyond the guidelines in individualising the use of antihypertensive drugs in older patients. Drugs Aging. 2019;36(8):675–685.
6.
DominguesDCarneiroRCostaI, et al.Therapeutic futility in cancer patients at the time of palliative care transition: an analysis with a modified version of the Medication Appropriateness Index. Palliat Med. 2015;29(7):643–651.
7.
OliveiraLFerreiraMORolaAMagalhaesMFerraz GoncalvesJ. Deprescription in advanced cancer patients referred to palliative care. J Pain Palliat Care Pharmacother. 2016;30(3):201–205.
8.
PoudelAYatesPRowettDNissenLM. Use of preventive medication in patients with limited life expectancy: a systematic review. J Pain Symptom Manage. 2017;53(6):1097–110.e1.
9.
RaijmakersNJvan ZuylenLFurstCJ, et al.Variation in medication use in cancer patients at the end of life: a cross-sectional analysis. Support Care Cancer. 2013;21(4):1003–1011.
10.
RiechelmannRPKrzyzanowskaMKZimmermannC. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17(6):745–748.
11.
SilveiraMJKazanisASShevrinMP. Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use. J Palliat Med. 2008;11(5):685–693.
12.
TurnerJPShakibSSinghalN, et al.Statin use and pain in older people with cancer: a cross-sectional study. J Am Geriatr Soc. 2014;62(10):1900–1905.
13.
AlkanAYasarAKarciE, et al.Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Support Care Cancer. 2017;25(1):229–236.
14.
BalducciLGoetz-PartenDSteinmanMA. Polypharmacy and the management of the older cancer patient. Ann Oncol. 2013;24(Suppl 7):vii36–40.
15.
PapeEMichelDScala-BertolaJ, et al.Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. Br J Clin Pharmacol. 2016;81(6):1195–1196.
16.
PopaMAWallaceKJBrunelloAExtermannMBalducciL. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol. 2014;5(3):307–314.
17.
RiechelmannRPTannockIFWangLSaadEDTabackNAKrzyzanowskaMK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.
18.
van LeeuwenRWBrundelDHNeefC, et al.Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108(5):1071–1078.
19.
van LeeuwenRWJansmanFGvan den BemtPM, et al.Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26(5):992–997.
20.
van LeeuwenRWSwartELBoomFASchuitenmakerMSHugtenburgJG. Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. BMC Cancer. 2010;10:679.
21.
ThompsonWLundbyCGraabaekT, et al.Tools for deprescribing in frail older persons and those with limited life expectancy: a systematic review. J Am Geriatr Soc. 2019;67(1):172–180.
KutnerJSBlatchfordPJTaylorDHJr, et al.Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691–700.
24.
DharmarajanTSChoiHHossainN, et al.Deprescribing as a clinical improvement Focus. J Am Med Dir Assoc. 2020;21(3):355–360.
25.
McKeanMPillansPScottIA. A medication review and deprescribing method for hospitalised older patients receiving multiple medications. Intern Med J. 2016;46(1):35–42.
26.
PotterKFlickerLPageAEtherton-BeerC. Deprescribing in frail older people: a randomised controlled trial. PLoS One. 2016;11(3):e0149984.
27.
EkbomTLindholmLHOdenA, et al.A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J Intern Med. 1994;235(6):581–588.
28.
GullaCFloEKjomeRLHuseboBS. Deprescribing antihypertensive treatment in nursing home patients and the effect on blood pressure. J Geriatr Cardiol. 2018;15(4):275–283.
29.
NelsonMRReidCMKrumHMuirTRyanPMcNeilJJ. Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian National Blood Pressure Study Cohort. BMJ. 2002;325(7368):815.
30.
StraandJFugelliPLaakeK. Withdrawing long-term diuretic treatment among elderly patients in general practice. Fam Pract. 1993;10(1):38–42.
31.
van KraaijDJJansenRWBruijnsEGribnauFWHoefnagelsWH. Diuretic usage and withdrawal patterns in a Dutch geriatric patient population. J Am Geriatr Soc. 1997;45(8):918–922.
32.
van KraaijDJJansenRWGribnauFWHoefnagelsWH. Use of diuretics and opportunities for withdrawal in a Dutch nursing home population. Neth J Med. 1998;53(1):20–26.
33.
WalmaEPHoesAWvan DoorenCPrinsAvan der DoesE. Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial. BMJ. 1997;315(7106):464–468.
34.
BlackDMSchwartzAVEnsrudKE, et al.Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–2938.
35.
Dawson-HughesBHarrisSSKrallEADallalGE. Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr. 2000;72(3):745–750.
36.
DeaneAConstancioLFogelmanIHampsonG. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord. 2007;8:3.
37.
McClungMRWagmanRBMillerPDWangALewieckiEM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017;28(5):1723–1732.
38.
MichalskaDStepanJJBassonBRPavoI. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2006;91(3):870–877.
39.
SilvaAGVieiraJGKuniiISLanaJMLazaretti-CastroM. The effects of discontinuing long term alendronate therapy in a clinical practice setting. Arq Bras Endocrinol Metabol. 2011;55(4):272–278.
40.
WattsNBChinesAOlszynskiWP, et al.Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19(3):365–372.
41.
CurtisJRWestfallAOChengHDelzellESaagKG. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int. 2008;19(11):1613–1620.
42.
NiznikJDHunnicuttJNZhaoX, et al.Deintensification of diabetes medications among veterans at the end of life in VA nursing homes. J Am Geriatr Soc. 2020;68(4):736–745.
43.
SjoblomPTengbladALofgrenUB, et al.Can diabetes medication be reduced in elderly patients? An observational study of diabetes drug withdrawal in nursing home patients with tight glycaemic control. Diabetes Res Clin Pract. 2008;82(2):197–202.
44.
RidkerPMDanielsonEFonsecaFA, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
45.
RidkerPMLonnEPaynterNPGlynnRYusufS. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;135(20):1979–1981.
46.
MagniPMacchiCMorlottiBSirtoriCRRuscicaM. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med. 2015;26(2):82–88.
47.
GrundySMStoneNJBaileyAL, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary. Circulation. 2019;139(25):e1046–e1081.
48.
QiKReeveEHilmerSNPearsonSAMatthewsSGnjidicD. Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm. 2015;37(5):949–957.
49.
BeckettNSPetersRFletcherAE, et al.Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898.
50.
MusiniVMTejaniAMBassettKWrightJM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2009;(4):CD000028.
51.
LimKKSivasampuSKhooEM. Antihypertensive drugs for elderly patients: a cross-sectional study. Singapore Med J. 2015;56(5):291–297.
52.
DickersonLMGibsonMV. Management of hypertension in older persons. Am Fam Physician. 2005;71(3):469–476.
53.
InderjeethCAChanKKwanKLaiM. Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. J Bone Miner Metab. 2012;30(5):493–503.
54.
van de GlindEMWillemsHCEslamiS, et al.Estimating the time to benefit for preventive drugs with the statistical process control method: an example with alendronate. Drugs Aging. 2016;33(5):347–353.
55.
WellsGCranneyAPetersonJ, et al.Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008a;(1):CD004523.
56.
WellsGACranneyAPetersonJ, et al.Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008b;(1):CD001155.
57.
ZhouMZhengYLiJ, et al.Upper gastrointestinal safety and tolerability of oral alendronate: a meta-analysis. Exp Ther Med. 2016;11(1):289–296.
58.
CummingsSRSan MartinJMcClungMR, et al.Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
59.
ZhouZChenCZhangJ, et al.Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol. 2014;7(5):2113–2122.
60.
AdlerAIStevensRJManleySE, et al.Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–232.
61.
BeckmanJACreagerMA. Vascular complications of diabetes. Circ Res. 2016;118(11):1771–1785.
62.
PoulsonJ. The management of diabetes in patients with advanced cancer. J Pain Symptom Manage. 1997;13(6):339–346.
63.
Diabetes UK. End of Life Diabetes Care: Full Strategy Document, 2nd ed. 2013.
LipskaKJKrumholzHSoonesTLeeSJ. Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA. 2016;315(10):1034–1045.
66.
MullerNKhuntiKKussO, et al.Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. Acta Diabetol. 2017;54(2):209–214.
67.
NicolucciAPintaudiBRossiMC, et al.The social burden of hypoglycemia in the elderly. Acta Diabetol. 2015;52(4):677–685.
68.
LindsayJDooleyMMartinJ, et al.The development and evaluation of an oncological palliative care deprescribing guideline: the ‘OncPal deprescribing guideline’. Support Care Cancer. 2015;23(1):71–78.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
